Accessibility Menu
Crism Therapeutics logo

Crism Therapeutics(LSE) CRTX

Market Cap£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-90%
5 YearN/A
1 Year+12%
1 Month+21%
£0.11
+0.35%
+0.00Today
Crism Therapeutics last closing stock price
MetricPriceDate
Last closeGBX 11.492026-08-20
Crism Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.88%GBX 10.752026-08-13
1 month+20.95%GBX 9.502026-07-21
3 month-0.09%GBX 11.502026-05-22
Year to date+14.9%GBX 10.002025-12-31
1 year+12.1%GBX 10.252025-08-20
Since inception-90.12%GBX 1.142006-03-15

Crism Therapeutics Financials at a Glance

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£0.00

Net Income (TTM)

-£2.52M

EPS (TTM)

-£0.05

P/E Ratio

-2.16

Dividend

£0.00

Beta (Volatility)

0.03 (Low)

Price

£0.11

Volume

434,406

Open

£0.11

Previous Close

£0.11

Daily Range

£0.11 - £0.12

52-Week Range

£0.08 - £0.18

Estimated Earnings Date

Sep 23, 2026

CRTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Crism Therapeutics

CRISM Therapeutics Corporation is focused on developing innovative drug delivery systems that enhance the effectiveness of cancer treatments targeting solid tumors. The company's flagship product, ChemoSeed, allows for precise localization of chemotherapy agents directly into tumor sites, particularly beneficial for glioma treatment.

Products and Services
  • ChemoSeed: A targeted drug delivery system for solid tumors
  • Innovative drug delivery technologies aimed at improving cancer treatment
  • Research and development in advanced oncology solutions
Growth Outlook
  • Established in 2016, the company has a strong foundation in biotechnology
  • Focus on glioma treatment positions CRISM in a niche market with high demand
  • Potential for expansion into other solid tumor therapies with ongoing R&D
Financial Highlights
  • Recent quarterly net income of -973,000 GBP, reflecting ongoing investment in R&D
  • Cash and cash equivalents of 1,128,000 GBP as of Q4 2025, providing operational liquidity
  • Current ratio of 4.35 indicates strong short-term financial health
CRISM Therapeutics Corporation operates in the biotechnology sector, emphasizing innovative solutions for cancer treatment. The company's ChemoSeed technology is designed to deliver chemotherapy directly to tumors, which may enhance treatment efficacy and reduce side effects. This targeted approach is particularly relevant for gliomas, a challenging type of brain tumor. The growth outlook for CRISM is promising, with a focus on expanding its product offerings and addressing unmet needs in oncology. The company’s commitment to research and development is evident in its financials, which show significant investment in R&D despite current net losses. The strong current ratio suggests that CRISM is well-positioned to manage its short-term obligations while pursuing long-term growth strategies. Investors may find CRISM Therapeutics Corporation an intriguing opportunity within the biotechnology space, particularly given its innovative approach to cancer treatment and the potential for future product development.
AI Generated • Aug 7, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Andrew James Webb

Website

www.crismtherapeutics.com

Headquarters

Road Town, TO, VG

CRTX Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-139.63%

Return on Capital

-148.94%

Return on Assets

-106.27%

Earnings Yield

-46.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

79.19M

Volume

434.41K

Avg. Volume

285.45K

Financials (TTM)

Gross Profit

-£129.02K

Operating Income

-£3.02M

EBITDA

-£2.69M

Operating Cash Flow

-£2.91M

Capital Expenditure

£1.00

Free Cash Flow

-£2.91M

Cash & ST Invst.

£1.13M

Total Debt

£0.00

Crism Therapeutics Performance Analysis

Crism Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 0N/A
20232023-12-31GBP 45,000N/A
20242024-12-31GBP 0N/A
20252025-12-31GBP 0N/A
Crism Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Crism Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP -0.2857.3%
20232023-12-31GBP -0.02-92.1%
20242024-12-31GBP -0.02-15.6%
20252025-12-31GBP -0.05176.2%
Crism Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3079.0%
Q42024-12-31-970.6%
Q22025-06-30-53.8%
Q42025-12-3115.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

£0.00

N/A

Gross Profit

-£106.00K

-1497.7%

Gross Margin

0.00%

N/A

Market Cap

£8.91MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

£2.23M

N/A

Employees

4

N/A

Net Income

-£973.00K

-1161.9%

EBITDA

-£1.19M

-2093.1%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

£1.13M

-74.3%

Total Debt

£0.00

N/A

Accounts Receivable

£242.00K

+1482.0%

Inventory

£0.00

N/A

Long Term Debt

£0.00

-100.0%

Short Term Debt

£0.00

-100.0%

Return on Assets

-1.06%

N/A

Return on Invested Capital

-1.49%

N/A

Free Cash Flow

-£1.10M

-17473.4%

Operating Cash Flow

-£1.10M

-28855.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TRX.LTissue Regenix Group plc
£0.07+0.00%
PRM.LProteome Sciences plc
£0.02-5.29%
TCF.LTheracryf Plc
£0.00+0.00%
N4P.LN4 Pharma Plc
£0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
BITOProShares Trust - ProShares Bitcoin ETF
$9.81+0.06%
SPCXSpace Exploration Technologies
$134.00-0.04%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.88-0.03%
IBITiShares Bitcoin Trust
$41.20+0.06%

Questions About CRTX

What is the current price of Crism Therapeutics?

Crism Therapeutics is trading at £0.11 per share.

What is the 52-week range for Crism Therapeutics?

Over the past 52 weeks, Crism Therapeutics has traded between £0.08 and £0.18.

How much debt does Crism Therapeutics have?

As of the most recent reporting period, Crism Therapeutics reported total debt of £0.00.

How much cash does Crism Therapeutics have on hand?

Crism Therapeutics reported £1.13M in cash and cash equivalents in its most recent financial results.

What is Crism Therapeutics’s dividend yield?

Crism Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services